Inogen (NASDAQ:INGN) EVP Sells 10,938 Shares of Stock

Posted by Brenda Bartman on Jul 6th, 2026

Inogen, Inc (NASDAQ:INGN – Get Free Report) EVP Boyer Jennifer Yi sold 10,938 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total transaction of $72,190.80. Following the completion of the transaction, the executive vice president owned 5,039 shares of the company’s stock, valued at $33,257.40. This represents a 68.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Inogen Stock Performance

Shares of INGN stock traded up $0.07 during midday trading on Monday, reaching $6.67. 157,740 shares of the company were exchanged, compared to its average volume of 304,270. The company’s 50 day moving average price is $6.60 and its two-hundred day moving average price is $6.42. The company has a market cap of $180.62 million, a P/E ratio of -7.33 and a beta of 1.58. Inogen, Inc has a 12 month low of $5.34 and a 12 month high of $9.13.

Inogen (NASDAQ:INGN – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical technology company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). Inogen had a negative net margin of 7.08% and a negative return on equity of 12.90%. The company had revenue of $85.11 million for the quarter, compared to analyst estimates of $82.35 million. As a group, sell-side analysts predict that Inogen, Inc will post -0.77 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on INGN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a report on Friday, May 8th. Freedom Capital raised shares of Inogen to a “strong-buy” rating in a research note on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

View Our Latest Stock Analysis on INGN

Hedge Funds Weigh In On Inogen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantinno Capital Management LP lifted its holdings in shares of Inogen by 78.1% in the first quarter. Quantinno Capital Management LP now owns 90,995 shares of the medical technology company’s stock valued at $562,000 after purchasing an additional 39,915 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Inogen by 203.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company’s stock valued at $3,622,000 after buying an additional 393,310 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Inogen by 15.5% during the first quarter. Assenagon Asset Management S.A. now owns 51,028 shares of the medical technology company’s stock valued at $315,000 after buying an additional 6,843 shares in the last quarter. Hsbc Holdings PLC raised its position in Inogen by 75.4% during the fourth quarter. Hsbc Holdings PLC now owns 60,482 shares of the medical technology company’s stock valued at $406,000 after buying an additional 25,998 shares during the period. Finally, Corient Private Wealth LLC acquired a new position in Inogen during the fourth quarter valued at $84,000. 89.94% of the stock is currently owned by hedge funds and other institutional investors.

Inogen Company Profile

(Get Free Report)

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.